Phenethanolamine derivatives for treatment of respiratory diseases

1. A compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof.

2. A compound according to claim 1 wherein said salt or solvate is pharmaceutically acceptable.

3. A compound according to claim 1 , wherein the salt is selected from the group consisting of a phenylcinnamate salt, a naphthoate salt, and a mandelate salt.

4. A pharmaceutical formulation comprising 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

5. A combination comprising a 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol or a pharmaceutically acceptable salt or solvate thereof, and one or more other therapeutic ingredients.

6. A combination according to claim 5 wherein the one or more other therapeutic ingredients is selected from the group consisting of a PDE4 inhibitor, a corticosteroid and an anti-cholinergic agent.

7. A combination according to claim 5 wherein the one or more other therapeutic ingredients is 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester.

8. A combination according to claim 5 wherein the one or more other therapeutic ingredients is 6,9-difluoro-11-hydroxy-16-methyl-17-[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene-17-carbothioic acid S-fluoromethyl ester.

9. A method for the treatment of a clinical condition in a mammal, for which a selective β 2 -adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol, or a pharmaceutically acceptable salt or solvate thereof.

10. A method according to claim 9 wherein the mammal is a human.

11. A method according to claim 10 wherein the clinical condition is asthma.

12. A method according to claim 10 wherein the clinical condition is COPD.

13. A compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol-triphenyl acetate.

14. A pharmaceutical formulation comprising a compound according to claim 13 , and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients.

15. A combination comprising a compound according to claim 13 , and one or more other therapeutic ingredients.

16. A combination according to claim 15 wherein the one or more therapeutic ingredients is selected from the group consisting of a PDE4 inhibitor, a corticosteroid, and an anti-cholinergic agent.

17. A combination according to claim 15 wherein the one or more therapeutic ingredients is 6α,9α-difluoro-17α-[(2-furanylcarbonyl)oxy]-11β-hydroxy-16α-methyl-3-oxo-androsta-1,4-diene-17β-carbothioic acid S-fluoromethyl ester.

18. A combination according to claim 15 wherein the one or more therapeutic ingredients is 6,9-difluoro-11-hydroxy-16-methyl-17-[(4-methyl-1,3-thiazole-5-carbonyl)oxy]-3-oxo-androsta-1,4-diene-17-carbothioic acid S-fluoromethyl ester.

19. A method for the treatment of a clinical condition in a mammal, for which a selective β 2 -adrenoreceptor agonist is indicated, which comprises administering a therapeutically effective amount of a compound according to claim 13 .

20. A method according to claim 19 wherein the mammal is a human.

21. A method according to claim 20 wherein the clinical condition is asthma.

22. A method according to claim 20 wherein the clinical condition is COPD.